Puma Biotechnology, Inc. (PBYI) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
Analysis Summary
Puma Biotechnology, Inc. reported revenue of $228.4M in the most recent fiscal year, growing at a 5-year CAGR of 0.3%.
Trailing-twelve-month margins: gross margin 74.8%, operating margin 13.2%, net margin 11.6%.
At the current price of $9.39, PBYI trades at a P/E of 16.72 and an ROE of 20.85%. Market capitalisation stands at $478M.
Balance sheet quality for PBYI: current ratio of 2.0, net cash position of $69.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $41.7M represents 134% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $9.39 |
| Market Cap | $478M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 16.72 |
| Price / Book | 3.30 |
| EV / EBITDA | 9.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 20.85% |
| Return on Invested Capital | 18.20% |
| Return on Assets | 13.86% |
| Gross Margin | 74.83% |
| Operating Margin | 13.16% |
| Net Margin | 11.55% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.91 |
| Piotroski F-Score | 7 |
| Altman Z-Score | -4.16 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PBYI | Puma Biotechnology, Inc. | $478M | 16.72 | 3.30 | 20.9% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +1.62% |
| 3 months | +24.21% |
| Year-to-date | +57.82% |
| 1 year | +116.36% |
| 3 years | +211.96% |
| 5 years | +36.09% |
52-Week Range
| 52-week High | $9.74 |
| 52-week Low | $4.30 |
| Avg Volume (90d) | 310K |
Related companies: ABEO · ALLO · ARCT · AVIR · ELDN · HUMA · SGMT
Explore sector: Healthcare · Biotechnology
More sections of PBYI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks